Inovio Files 8-K on Shareholder Vote Submission

TL;DR

**Inovio filed a routine 8-K about a shareholder vote, no big news here.**

AI Summary

Inovio Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the company is providing information about a recent shareholder vote, which is a routine disclosure for public companies. For investors, this matters because it signals transparency and adherence to regulatory requirements, but the filing itself doesn't reveal the outcome or specific details of the vote, so its direct impact on stock value is currently neutral.

Why It Matters

This filing is a standard regulatory update, indicating Inovio is keeping shareholders informed about corporate governance, but it doesn't contain new financial or operational news.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing and does not introduce new financial or operational risks to the company.

Analyst Insight

A smart investor would note this routine filing but await further disclosures for specific details on the shareholder vote outcomes before making any investment decisions.

Key Players & Entities

• Inovio Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 12, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Inovio Pharmaceuticals, Inc.
• 001-14888 (dollar_amount) — Commission File Number for Inovio Pharmaceuticals, Inc.
• 33-0969592 (dollar_amount) — IRS Employer Identification No. for Inovio Pharmaceuticals, Inc.

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark

Filing Documents

• d722280d8k.htm (8-K) — 28KB
• 0001193125-24-007674.txt ( ) — 147KB
• ino-20240112.xsd (EX-101.SCH) — 3KB
• ino-20240112_lab.xml (EX-101.LAB) — 18KB
• ino-20240112_pre.xml (EX-101.PRE) — 11KB
• d722280d8k_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 12, 2024, Inovio Pharmaceuticals, Inc. (the " Company ") convened a special meeting of stockholders (the " Special Meeting ") to adopt and approve a proposed amendment to the Company's Certificate of Incorporation, as amended to date, and authorize the Board of Directors of the Company (the " Board "), in its sole discretion, to effect a reverse stock split of the outstanding shares of common stock of the Company (the " Common Stock ") at any time on or before the one year anniversary of the Special Meeting, at a reverse stock split ratio ranging from 1-for-10 to 1-for-50, as determined by the Board at a later date (the " Reverse Stock Split Proposal "). At the Special Meeting, the stockholders voted on the Reverse Stock Split Proposal, which is described as Proposal 1 in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 28, 2023 (the " Proxy Statement "), and a proposal to adjourn the Special Meeting if necessary to solicit additional proxies if there are insufficient votes to adopt the Reverse Stock Split Proposal, as described in Proposal 2 in the Proxy Statement (the " Adjournment Proposal ," and together with the Reverse Stock Split Proposal, the " Proposals "). Of the 272,989,736 shares of Common Stock entitled to vote as of November 16, 2023 (the " Record Date "), including shares issuable upon conversion of outstanding shares of Series C Cumulative Convertible Preferred Stock of the Company as of the Record Date, 146,265,973 shares, or 53.6%, were present or represented by proxy at the Special Meeting. The following is a summary of the voting results: Proposal 1: Reverse Stock Split Proposal . The votes were cast as follows: For Against Abstain 96,534,629 48,857,255 874,089 The Reverse Stock Split Proposal was approved. Proposal 2: Adjournment Proposal . The votes were cast as follows: For Against Abstain 106,

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: January 12, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR